Physician profile
Kendra J Hurst
NPI 1346273638
$1,396.49
in general payments reported to CMS, 2019-2025
15 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.72 · 2023: $424 · 2024: $355 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $276.89 | 2023-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $241.66 | 2024-2025 | Intracept |
| Nevro Corp. | $226.92 | 2023-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.83 | 2023-2025 | Relistor |
| Medtronic, INC. | $106.09 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Averitas Pharma INC. | $95.51 | 2023-2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $54.83 | 2023 | Ztlido |
| Spr Therapeutics, INC | $50.46 | 2023-2025 | Sprint Pns System |
| Abbvie INC. | $44.15 | 2023-2025 | |
| Valinor Pharma, LLC | $35.23 | 2025 | Movantik |
| Forte Bio-Pharma LLC | $32.22 | 2023 | Prolate, Nalocet |
| Abbott Laboratories | $20.73 | 2023 | Proclaim |
| Protega Pharmaceutials INC | $20.45 | 2025 | Roxybond |
| Globus Medical, INC. | $18.44 | 2025 | Senza |
| Bioventus LLC | $16.08 | 2025 | Gelsyn-3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.